Intellia Therapeutics Inc (NASDAQ:NTLA) had its price objective increased by Leerink Swann from $29.00 to $37.00 in a research note issued to investors on Tuesday. The firm currently has an outperform rating on the stock. The analysts noted that the move was a valuation call.
Several other equities analysts have also recently weighed in on the company. Cann reaffirmed a market perform rating on shares of Intellia Therapeutics in a report on Monday, July 17th. Jefferies Group LLC reaffirmed a buy rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a report on Saturday, July 22nd. Oppenheimer Holdings, Inc. started coverage on Intellia Therapeutics in a report on Tuesday, July 18th. They issued a market perform rating for the company. Chardan Capital cut Intellia Therapeutics from a buy rating to a neutral rating and set a $20.00 price objective for the company. in a report on Tuesday, August 29th. Finally, Barclays PLC started coverage on Intellia Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $29.00 price objective for the company. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $29.50.
Shares of Intellia Therapeutics (NASDAQ:NTLA) traded down 16.1690% on Tuesday, hitting $26.0882. The company had a trading volume of 1,192,620 shares. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $33.34. The firm has a 50-day moving average price of $26.55 and a 200 day moving average price of $26.44. The company’s market capitalization is $942.10 million.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The business had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 33.90% and a negative net margin of 209.87%. The firm’s quarterly revenue was up 49.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.22) EPS. Equities analysts expect that Intellia Therapeutics will post ($1.78) EPS for the current year.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/01/intellia-therapeutics-inc-ntla-price-target-raised-to-37-00-at-leerink-swann.html.
Several institutional investors have recently bought and sold shares of NTLA. Russell Investments Group Ltd. acquired a new position in shares of Intellia Therapeutics during the 1st quarter worth $137,000. Wells Fargo & Company MN raised its holdings in shares of Intellia Therapeutics by 231.7% during the 1st quarter. Wells Fargo & Company MN now owns 10,945 shares of the company’s stock worth $154,000 after buying an additional 7,645 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Intellia Therapeutics by 5.6% during the 1st quarter. Bank of New York Mellon Corp now owns 31,676 shares of the company’s stock worth $446,000 after buying an additional 1,682 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 904,708 shares of the company’s stock worth $12,747,000 after buying an additional 33,925 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 6.0% during the 1st quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after buying an additional 4,291 shares in the last quarter. 47.77% of the stock is owned by institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics Inc and related companies.